US EditionMan's deadly brain cancer tumor disappears after experimental drug trial
GREATER LONDON, ENGLAND, JUL 20 – The immunotherapy trial, funded by a £1 million campaign, aims to improve glioblastoma survival where typically only 5% survive beyond five years, following one patient’s complete remission.
- A new immunotherapy trial for glioblastoma is seeking 16 patients and is established in memory of Baroness Margaret McDonagh, who passed away from the disease.
- Patients will receive the drug ipilimumab to strengthen their immune systems before standard treatment, and they will utilize their strongest immune response.
- Ben Trotman, a patient in a previous trial, saw his tumor vanish, with no signs of glioblastoma for over two years, which is significant given typical survival rates.
- Dr. Paul Mulholland, who is leading the trial, stated that having clear scans is unusual for glioblastoma patients.
14 Articles
14 Articles
Cancer Patient’s Deadly Brain Tumor Disappears After Taking Experimental New Drug
A groundbreaking case out of the United Kingdom is bringing hope to those battling glioblastoma, one of the deadliest forms of brain cancer. The post Cancer Patient’s Deadly Brain Tumor Disappears After Taking Experimental New Drug appeared first on Slay News.
British man's fast-growing brain tumour vanishes after taking new drug in NHS trial
A groundbreaking NHS immunotherapy study targeting the most lethal type of brain tumour has begun enrolling participants following an extraordinary case where a patient's cancer completely disappeared.The research focuses on glioblastoma and will involve 16 participants receiving the drug ipilimumab before conventional therapies, when patients' immune responses remain strongest.The initiative emerged after Ben Trotman, who participated in an ear…
Patients sought as NHS trials new treatment for deadliest brain cancer - after man miraculously sees tumour vanish
The NHS is looking for patients in a trial for a new type of treatment for the deadliest form of brain cancer, after one man had remarkable results that saw his tumour disappear.
Coverage Details
Bias Distribution
- 46% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
